References
- SekulicAMigdenMROroAEEfficacy and safety of vismodegib in advanced basal-cell carcinomaN Engl J Med2012366232171217922670903
- CaroILowJThe role of the hedgehog signaling pathway in the development of basal cell carcinoma and opportunities for treatmentClin Cancer Res201016133335333920439455
- RubinALChenEHRatnerDBasal-cell carcinomaN Engl J Med2005353212262226916306523
- BurnessCBScottLJSonidegib: a review in locally advanced basal cell carcinomaTarget Oncol201611223924626867946
- MohanSVChangALSAdvanced basal cell carcinoma: epidemiology and therapeutic innovationsCurr Dermatol Rep201431404524587976
- National Comprehensive Cancer NetworkNCCN Clinical Practice Guidelines in Oncology: Basal Cell Skin CancerNCCN Available from: www.nccn.org/professionals/physician_gls/pdf/nmsc.pdf. Version 22016Accessed December 21, 2016
- PuigSBerrocalAManagement of high-risk and advanced basal cell carcinomaClin Transl Oncol201517749750325643667
- AvrilMFAuperinAMargulisABasal cell carcinoma of the face: surgery or radiotherapy? Results of a randomized studyBr J Cancer19977611001069218740
- DlugoszAAgrawalSKirkpatrickPVismodegibNat Rev Drug Disco201211437438
- HolohanCSchaeybroeckSVLongleyDBJohnstonPGCancer drug resistance: an evolving paradigmNat Rev Cancer20131371472624060863
- WahidMJawedAMandalRKVismodegib, itraconazole and sonidegib as hedgehog pathway inhibitors and their relative competencies in the treatment of basal cell carcinomasCrit Rev Oncol Hematol20169823524126614022
- DijkgraafGJAlickeBWeinmannLSmall molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistanceCancer Res201171243544421123452
- Erivedge® (Vismodegib) [package insert]US Prescribing Information2012
- KishTCorryLSonidegib (Odomzo) for the systemic treatment of adults with recurrent, locally advanced basal cell skin cancerPharm Ther2016415322325
- Odomzo® (Sonidegib) [package insert]US Prescribing Information2015
- ZollingerMLozac’hFHurhEAbsorption, distribution, metabolism, and excretion (ADME) of 14C-sonidegib (LDE225) in healthy volunteersCancer Chemother Pharmacol2014741637524817600
- European Medicines AgencySummary of product characteristics (Odomzo)LondonEuropean Medicines Agency2015
- Odomzo® (Sonidegib) [package insert]US Prescribing Information2015US Food and Drug Administration10903 New Hampshire AvenueSilver SpringMD 20993
- MigdenMRGuminskiAGutzmerRTreatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trialLancet Oncol201516671672825981810
- WHO WHO Handbook for Reporting Results for Cancer TreatmentGenevaWorld Health Organization1979
- US Department of Health and Human ServicesNational Cancer InstituteCommon Terminology Criteria for Adverse Events (CTCAE) Version 4.032010 Available from: https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdfAccessed November 14, 2016
- ChenLSilapuntSMigdenMRSonidegib for the treatment of advanced basal cell carcinoma: a comprehensive review of sonidegib and the BOLT trial with 12-month updateFuture Oncol201612182095210527189494
- DreierJDummerRFeldererLNägeliMGobbiSKunstfeldREmerging drugs and combination strategies for basal cell carcinomaExpert Opin Emerg Drugs201419335336524773312
- PriclSCortelazziBColVDSmoothened (SMO) receptor mutations dictate resistance to vismodegib in basal cell carcinomaMol Oncol20149238939725306392
- DanialCSarinKYOroAEChangALAn investigator-initiated open-label trial of sonidegib in advanced basal cell carcinoma patients resistant to vismodegibClin Cancer Res20162261325132926546616
- Ni ChonghaileTLetaiAMimicking the BH3 domain to kill cancer cellsOncogene200827suppl 1S149S15719641500
- OakesSRVaillantFLimESensitization of BCL-2 expressing breast tumors to chemotherapy by the BH3 mimetic ABT-737Proc Natl Acad Sci U S A201210982766277121768359